SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. today announced the hiring of Wilhelm Stahl, Ph.D., as Chief Technology Officer and Senior Vice President. Dr. Stahl will lead Tricida’s chemistry, manufacturing and controls (CMC) and analytical departments and be responsible for directing manufacturing and supply chain activities, from scale-up to registration and commercialization.
"We are delighted to welcome Willi Stahl to our team. Willi’s impressive track record overseeing supply chain management for polymer-based pharmaceuticals while advancing manufacturing to commercial scale will be an invaluable asset as Tricida moves into late-stage development and begins preparation for commercial launch,” said Gerrit Klaerner, Ph.D., Tricida’s CEO, President and Board Member. “Bringing Willi into the leadership role of our manufacturing and technology programs is a key step in Tricida's continued preparation for the commercial launch of our first-in-class drug candidate TRC101.”
Dr. Stahl has over 25 years of experience with clinical and commercial product development and manufacturing of pharmaceuticals. Dr. Stahl joins Tricida from Relypsa, Inc., a Vifor Pharma company, where he served as Chief Technology Officer and led manufacturing and supply chain activities during late stage development, scale up and launch of Relypsa’s novel hyperkalemia treatment Veltassa® (patiromer). Prior to joining Relypsa, Dr. Stahl was a Managing Partner at Rondaxe Enterprises, a global CMC consulting firm, and headed Saltigo GmbH’s Pharmaceutical Custom Manufacturing Business. Prior to Saltigo, he held multiple positions with increasing responsibility in pharmaceutical R&D at Bayer, Aventis, HMR and Hoechst. Dr. Stahl received his Ph.D. from the Institute for Organic Chemistry and Biochemistry at the University of Bonn and joined Prof. K.C. Nicolaou’s lab at the Research Institute of Scripps Clinic before starting his career in industry.
“I am excited to join the Tricida team to support the ongoing development of TRC101, a first in class drug candidate with incredible market potential,” said Wilhelm Stahl, Ph.D. “With extraordinarily positive topline Phase 1/2 results and relatively low cost of goods, TRC101 is uniquely positioned for commercial success.”
Tricida, Inc. is a privately-held, clinical stage, biopharmaceutical company focused on the discovery and development of non-absorbed therapies. Tricida’s lead investigational drug candidate, TRC101, represents a first-in-class approach to the treatment of metabolic acidosis, a common complication of chronic kidney disease (CKD) that can result in increased mortality, accelerated progression of kidney disease, progressive muscle breakdown and exacerbation of bone disease. In January 2016, the FDA accepted Tricida’s Investigational New Drug (IND) application for TRC101 and the company has since successfully completed a Phase 1/2 clinical research program in which the safety, tolerability and efficacy of TRC101 were evaluated in a double-blind placebo-controlled trial of subjects with chronic kidney disease and low serum bicarbonate.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, including, for example, potential therapeutic capabilities, potential medical need and market size, and our expected timeline of development. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. For example, many drug candidates entering Phase 3 trials do not become approved drugs. The forward-looking statements contained in this press release reflect Tricida’s current views with respect to future events, and Tricida does not undertake and specifically disclaims any obligation to update any forward-looking statements.
For more information, visit www.tricida.com.